Clinical Trial 45002

Las Vegas, NV 89102


Title: Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic medications. (GRATITUTE II)


This is a randomized, double-blind, placebo-controlled study that will assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant in obese patients with schizophrenia who are currently taking olanzapine, risperidone, paliperidone, or quetiapine.

Patients who meet the criteria for the Study CORT118335-877 will be randomized on Day 1 to receive 600 mg miricorilant, 900 mg miricorilant, or placebo for 26 weeks.

Qualified Participants Must:

• Be 18 Years to 65 Years
• Have a diagnosis of schizophrenia
• Are currently taking olanzapine, risperidone, paliperidone, or quetiapine and have gained weight from treatment while on these medications
• Must be on a stable dose of medication for 1 month prior to screening
• Have a BMI 30 kg/m2 or higher

Qualified Participants May Receive:

study related care at no cost

compensation for time and travel for study visits. 

Available At:

Altea Research Institute
3012 W Charleston Blvd suite 100
Las Vegas, NV 89102
View Clinic Location


If you or someone you care for is interested in participating and lives within 25 miles of the location shown, please complete the form below and click 'Submit'

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.